Aytu BioPharma to Present at Lytham Partners Fall 2023 Investor Conference on October 17, 2023
Aytu BioPharma, a leading pharmaceutical company focused on bringing innovative therapeutics to market, has exciting news to share. The company’s Chief Executive Officer, Josh Disbrow, will be presenting and hosting one-on-one meetings with investors at the highly anticipated Lytham Partners Fall 2023 Investor Conference. This virtual event is scheduled to take place on October 17, 2023.
Investors and industry enthusiasts alike will have the opportunity to watch Aytu BioPharma’s webcast presentation, which will be available for viewing on the company’s website at 7:00am ET on Tuesday, October 17, 2023. The webcast can be accessed at https://investors.aytubio.com/ or https://wsw.com/webcast/lytham9/aytu/2072440. For those unable to catch the live presentation, the webcast will be archived and available for replay.
In addition to the webcast, Aytu BioPharma’s management team will be participating in virtual one-on-one meetings throughout the event. Investors interested in arranging a meeting with the company’s management can reach out to Lytham Partners at 1×email@example.com or register at https://www.lythampartners.com/fall2023invreg/.
Aytu BioPharma is a pharmaceutical powerhouse, known for its portfolio of commercial prescription therapeutics and consumer health products. The company’s prescription offerings include Adzenys XR-ODT® and Cotempla XR-ODT®, both extended-release orally disintegrating tablets designed to treat attention deficit hyperactivity disorder (ADHD). Aytu BioPharma also offers Karbinal® ER, an extended-release antihistamine suspension used to treat various allergic conditions. Additionally, the company provides Poly-Vi-Flor® and Tri-Vi-Flor®, two fluoride-based prescription vitamin product lines available in different formulations for infants and children with fluoride deficiency.
Aytu BioPharma’s consumer health segment is equally impressive, offering a range of over-the-counter medicines and consumer health products. These products address common conditions such as diabetes, allergies, hair regrowth, and gastrointestinal issues.
With a commitment to improving the lives of patients and consumers, Aytu BioPharma continues to make significant strides in the pharmaceutical industry. The company’s participation in the Lytham Partners Fall 2023 Investor Conference further demonstrates its dedication to connecting with investors and sharing its vision for the future.
For more information about Aytu BioPharma and its innovative products, please visit their official website at aytubio.com. Investors can reach out to Mark Oki, the Chief Financial Officer of Aytu BioPharma, at firstname.lastname@example.org. Alternatively, they can contact Robert Blum or Roger Weiss of Lytham Partners at AYTU@lythampartners.com.
Aytu BioPharma’s presence at the Lytham Partners Fall 2023 Investor Conference is sure to generate excitement and interest within the industry. Stay tuned for updates on the company’s groundbreaking developments and future endeavors.